申请人:H. LUNDBECK A/S
公开号:EP0994107A1
公开(公告)日:2000-04-19
2-Aminocarboxylic acid compounds substituted with 5-arylisoxazol-4-yl or 5-arylisothiazol-4-yl and having general formula (I), wherein A is a bond or a spacer group; B is a group -CH(NR'R'')-COOH wherein R' and R'' are independently hydrogen or C1-6 alkyl, or B is a group of formula (II), wherein R2, R3 and R4 are substituents; or R3 and R4 or R4 and R2 are connected in order to form a ring; E is O, S, COO, (CH2)n-COO, O-(CH2)n-COO or S-(CH2)n-COO wherein n is 1-6, 5-tetrazolyl, 5-tetrazolyl-C1-6 alkyl, 3-hydroxyisoxazolyl or 3-hydroxyisoxazolyl-C1-6 alkyl; D is O or S; and R1 is an optionally substituted aryl or heteroaryl group; are excitatory amino acid receptor ligands useful in the treatment of cerebral ischaemia, Huntington's disease, epileptic disorders, Parkinson's disease, Alzheimer's disease, schizophrenia, pain, depression and anxiety.
用5-芳基异噁唑-4-基或5-芳基异噻唑-4-基取代的2-氨基羧酸化合物,具有通用式(I),其中A是键或间隔基;B是基-CH(NR'R'')-COOH,其中R'和R''独立地是氢或C1-6烷基,或者B是式(II)中的基,其中R2、R3和R4是取代基;或R3和R4或R4和R2相连以形成环;E是O、S、COO、(CH2)n-COO、O-(CH2)n-COO或S-(CH2)n-COO,其中n为1-6,5-四唑基,5-四唑基-C1-6烷基,3-羟基异噁唑基或3-羟基异噁唑基-C1-6烷基;D是O或S;R1是可选择取代的芳基或杂环基;在治疗脑缺血、亨廷顿病、癫痫障碍、帕金森病、阿尔茨海默病、精神分裂症、疼痛、抑郁症和焦虑症中有用的兴奋性氨基酸受体配体。